Cytokeratin 8 Antibody (C51): sc-8020

Cytokeratin 8 Antibody (C51) is a mouse monoclonal IgG1 kappa light chain antibody that detects Cytokeratin 8 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-Cytokeratin 8 antibody (C51) is available in both non-conjugated and multiple conjugated forms, such as agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® conjugates. Cytokeratin 8, part of a diverse group of intermediate filament proteins, plays a crucial role in maintaining structural integrity of epithelial cells and is essential for cellular differentiation and tissue specialization. Cytokeratin 8 is predominantly located in cytoplasm of simple epithelial cells, where Cytokeratin 8 forms a network providing mechanical support and resilience against stress. Proper localization of Cytokeratin 8 is vital, as misexpression can lead to pathological conditions, including various carcinomas. Expression of Cytokeratin 8 is often upregulated in epithelial-derived tumors, making Cytokeratin 8 a significant marker for cancer diagnosis and prognosis. Presence of Cytokeratin 8 in squamous cell carcinomas derived from stratified epithelia has been associated with poor clinical outcomes, highlighting potential as a therapeutic target. Cytokeratin 8 and 18 pair is typically expressed in simple epithelia, and abnormal expression in stratified epithelial cells can indicate malignancy, further underscoring importance in cancer research and treatment strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 8 Antibody (C51) References:

1. Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines.  |  Fujita, J., et al. 1999. Br J Cancer. 81: 769-73. PMID: 10555744
2. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype.  |  Raul, U., et al. 2004. Int J Cancer. 111: 662-8. PMID: 15252834
3. Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells.  |  Gires, O., et al. 2005. Biochem Biophys Res Commun. 328: 1154-62. PMID: 15707998
4. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity.  |  Fillies, T., et al. 2006. BMC Cancer. 6: 10. PMID: 16412231
5. CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck.  |  Gires, O., et al. 2006. Biochem Biophys Res Commun. 343: 252-9. PMID: 16540085
6. Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization.  |  Wang, Y., et al. 2008. Cancer Lett. 265: 188-96. PMID: 18353540
7. Cytokeratin 8 is expressed in human corneoconjunctival epithelium, particularly in limbal epithelial cells.  |  Merjava, S., et al. 2011. Invest Ophthalmol Vis Sci. 52: 787-94. PMID: 20926822
8. Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ.  |  Leube, RE., et al. 1986. Differentiation. 33: 69-85. PMID: 2434381
9. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.  |  Guo, D., et al. 2018. Int J Mol Sci. 19: PMID: 29443941
10. Evaluation of a new tumor marker for cytokeratin 8 and 18 fragments in healthy individuals and prostate cancer patients.  |  Silén, A., et al. 1994. Prostate. 24: 326-32. PMID: 7516071
11. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients.  |  Silén, A., et al. 1995. Scand J Clin Lab Invest. 55: 153-61. PMID: 7545308
12. Cytokeratin expression in normal and (pre)malignant head and neck epithelia: an overview.  |  van der Velden, LA., et al. 1993. Head Neck. 15: 133-46. PMID: 7680025

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Cytokeratin 8 Antibody (C51) has 62 citations in a variety of scientific publications.

Primary antibodies like Anti-Cytokeratin 8 Antibody (C51) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Cytokeratin 8 Antibody (C51) Specifications

Alternate Product Name: KRT8

Product Clone Name: C51

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Cytokeratin 8

Epitope Species: human

Product Reactivity/Detection: Cytokeratin 8

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 62 citations in various scientific publications

Available Conjugates/Forms for Cytokeratin 8 Antibody (C51): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin